Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ethyl loflazepate is a benzodiazepine derivative used primarily as an anxiolytic and sedative. It also possesses anticonvulsant and skeletal muscle relaxant properties. Ethyl loflazepate acts as a prodrug, with its main pharmacological effects mediated by its active metabolite, descarboxyloflazepate, which is a benzodiazepine receptor agonist. The drug exerts its effects by acting as a positive allosteric modulator of the GABA-A receptor complex, enhancing the inhibitory neurotransmitter GABA's effect in the central nervous system. It has been approved for use in conditions such as anxiety (including post-trauma anxiety), generalized anxiety disorder (GAD), panic attacks, obsessive–compulsive disorder, delirium tremens, and anxiety associated with severe neuropathic pain[1][5][6]. Ethyl loflazepate is not approved for marketing in the United States but is commercialized under various brand names in other countries.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ethyl loflazepate.